Nuzenio

Tradingview Cullinan Therapeutics

Tradingview Cullinan Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 7 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Cullinan Therapeutics, Inc. Stock 12‑Month Price Target Raised to $33, Implies 87% Upside - TradingViewTradingView · Thu, 06 Aug 2026 17:20:11 GMTCullinan Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 13:12:27 GMTCullinan Therapeutics Q2 net loss narrows - TradingViewTradingView · Thu, 06 Aug 2026 11:33:41 GMTCullinan Therapeutics 3Q 2026: Revenue $0 Net loss $53.7M, EPS $(0.81) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:21:02 GMTCGEM: Pipeline advances and strong cash position support growth and late-stage clinical milestones - TradingViewTradingView · Thu, 06 Aug 2026 11:16:47 GMTCullinan Therapeutics reports Q2 2026 net loss of $53.7M, cash and investments $356.0M - TradingViewTradingView · Thu, 06 Aug 2026 11:13:01 GMTCGEM Q2'26 Earnings: revenue estimate is 0 USD - TradingViewTradingView · Thu, 30 Jul 2026 07:00:00 GMT

Timeline

Thu, 06 Aug 2026 17:20:11 GMTCullinan Therapeutics, Inc. Stock 12‑Month Price Target Raised to $33, Implies 87% Upside - TradingView
Thu, 06 Aug 2026 13:12:27 GMTCullinan Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView
Thu, 06 Aug 2026 11:33:41 GMTCullinan Therapeutics Q2 net loss narrows - TradingView
Thu, 06 Aug 2026 11:21:02 GMTCullinan Therapeutics 3Q 2026: Revenue $0 Net loss $53.7M, EPS $(0.81) — 10-Q Summary - TradingView
Thu, 06 Aug 2026 11:16:47 GMTCGEM: Pipeline advances and strong cash position support growth and late-stage clinical milestones - TradingView
Thu, 06 Aug 2026 11:13:01 GMTCullinan Therapeutics reports Q2 2026 net loss of $53.7M, cash and investments $356.0M - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Cullinan Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.